Clinical Practice
Selegiline Patch for TRD: A PMHNP Prescribing Protocol
The selegiline patch (EMSAM) is the MAOI with no diet rules at 6 mg. A PMHNP protocol for candidates, washouts, dosing, tyramine, and monitoring in TRD.
Read More →
TL;DR
- Three out of four first-attempt PMHNP LAI starts fail on loading, oral overlap, or interval — not on the molecule itself.
- Aripiprazole LAIs (Maintena, Asimtufii) require 14 days of oral aripiprazole overlap after the first injection; Asimtufii additionally requires two months of prior stability on oral or monthly LAI.
- Paliperidone palmitate (Sustenna) loads with 234 mg on day one and 156 mg on day eight — no oral overlap needed because the loading regimen handles it.
- Risperdal Consta requires three weeks of oral overlap; Uzedy (subcutaneous risperidone) does not — and Uzedy now carries a 2026 FDA indication for bipolar I maintenance.
- Every modern LAI has a published missed-dose window; operating from memory is the fastest path to rehospitalization.
- The 90-day window is where adherence is won or lost — one injection plus one phone call is a dropout pipeline.
On this page
Three out of four PMHNPs who try to start a patient on a long-acting injectable antipsychotic do it wrong on the first attempt. They under-load. They over-overlap. They schedule the second dose at the wrong interval. The patient relapses, the chart blames “non-adherence,” and the clinician quietly stops recommending LAIs.
The fix is mechanical. Every modern LAI ships with a published transition window, a published overlap rule, and a published re-initiation protocol for missed doses. Most new PMHNPs have never seen the table all in one place.
“Patients do not relapse on LAIs because the medication failed,” says Lindsay Hill, DNP, PMHNP-BC, founder of the Psych NP Fellowship. “They relapse because the prescriber treated the LAI like an oral med that lasts a month. The whole point is that it does not — the kinetics drive every clinical decision.”
The 2026 picture has three new variables. Uzedy (risperidone) now carries an FDA indication for bipolar I maintenance. Abilify Asimtufii (aripiprazole) is the every-two-month standard for stable patients. Invega Hafyera (paliperidone) is the every-six-month formulation for the most stable patients, but only after a specific stair-step from PP1M to PP3M to PP6M. Each transition has its own arithmetic.
When to actually offer an LAI in 2026
The evidence base on LAIs shifted in the last five years. Schizophrenia patients on an LAI have roughly half the relapse rate of patients on the same molecule taken orally — not because the drug is more potent, but because adherence stops being a variable. The most recent practice guidance from the American Psychiatric Association recommends offering an LAI to any patient with schizophrenia for whom maintenance treatment is indicated, not just patients with documented non-adherence.
First-episode psychosis is the highest-leverage moment. Patients started on an LAI within the first year of diagnosis have lower rates of rehospitalization and a longer time to first relapse than patients maintained on oral antipsychotics. New PMHNPs were trained to reserve LAIs for “non-adherent” patients. The 2026 standard is to offer them earlier.
Bipolar I maintenance is the newest indication. Uzedy carries it now. Abilify Maintena and Abilify Asimtufii have carried it for years. The maintenance evidence base for bipolar I on aripiprazole LAI is strong enough that AANP and APA both now recommend considering LAI maintenance for bipolar I patients with a history of mixed features or rapid cycling.
The decision to offer an LAI happens before the decision of which one. Frame the conversation as a delivery-method choice — not as a punishment for missed pills. Patients respond differently when the prescriber leads with “this is the format that gives you the lowest relapse risk.”
The transition arithmetic by molecule
Three transition rules cover most of the 2026 LAI prescribing in psychiatric NP practice.
Aripiprazole LAI. Stabilize the patient on oral aripiprazole 10–30 mg daily for at least two weeks before the first injection. For Abilify Maintena (monthly), give the first 400 mg injection and continue oral aripiprazole at the same dose for 14 days, then taper the oral. For Abilify Asimtufii (every two months), the patient must be stabilized on oral aripiprazole or on monthly LAI for at least two months before the first 960 mg injection — the 14-day oral overlap after the first injection is unchanged. Missed-dose rules are tight: if more than 8 weeks but up to 14 weeks since the last Asimtufii injection, restart oral aripiprazole for 14 days with the next injection.
Paliperidone palmitate. The PP1M (Invega Sustenna) loading dose is 234 mg deltoid on day one, 156 mg deltoid on day eight, then a monthly maintenance dose typically of 117 mg. No oral overlap is required because the day-one and day-eight doses do the loading. Transition to PP3M (Invega Trinza) requires at least four months of PP1M with the last two doses identical, then the PP3M dose is 3.5× the last PP1M dose. Transition to PP6M (Invega Hafyera) requires either at least four months of PP1M at 156 mg or 234 mg with the last two doses the same, or at least one full PP3M cycle at 546 mg or 819 mg. The PP6M dose is 2× the last PP3M dose or 6.5× the last PP1M dose.
Risperidone LAI. The older Risperdal Consta (intramuscular every two weeks) requires three weeks of oral risperidone overlap because the microspheres do not release meaningful drug until week three. The newer Uzedy (subcutaneous, monthly or every two months) does not require oral overlap at initiation — the formulation releases therapeutic levels within the first week. For Uzedy bipolar I maintenance, the monthly schedule is the labeled regimen; the every-two-month schedule is schizophrenia-only per current labeling.
What most people get wrong
The most expensive error is treating the LAI as if it were a slow-release oral medication. It is not. The injection establishes a multi-week pharmacokinetic envelope. If the prescriber injects, then waits a month, then assesses, then adjusts — they are two months behind the patient.
The second error is skipping the oral overlap when it is required. Aripiprazole LAI without the 14-day oral overlap routinely produces sub-therapeutic plasma levels in week two and week three. The patient feels worse, blames the injection, and refuses the second dose. The clinician records “patient declined LAI.” The chart looks like a tolerability failure when it was a loading failure.
The third error is the opposite — overlapping when no overlap is needed. Paliperidone palmitate does not need an oral overlap because the loading regimen handles it. Continuing oral risperidone or oral paliperidone past day eight wastes pills, raises side-effect risk, and creates a false sense that the LAI alone is not working.
The fourth error is the missed-dose protocol. Every LAI has a labeled window for “what if the patient misses the dose.” Operating from memory or from outdated label data is the fastest way to a rehospitalization. Pull the current label every time.
Monitoring the first 90 days
A patient on a new LAI needs more touchpoints in the first 90 days, not fewer. The injection date is not a substitute for clinical assessment.
Week one. Phone or telehealth check for injection-site reactions, akathisia, and sedation. Aripiprazole patients should be specifically asked about restlessness — aripiprazole-induced akathisia onset peaks in the first two weeks of LAI therapy and is the leading cause of first-month discontinuation.
Week four. In-person or telehealth visit. PHQ-9 and a positive-symptom checklist if relevant. For paliperidone or risperidone patients, prolactin and a metabolic panel are appropriate at baseline, again at 12 weeks, then annually. For aripiprazole patients, the metabolic panel can wait until 12 weeks if there are no risk factors.
Weeks 8 to 12. Second injection (monthly LAIs) or the planned second dose for the every-two-month formulations. Symptoms should be at or near baseline. If they are not, the LAI dose should be adjusted before the next interval rather than waiting another two months.
The Texas LAI Antipsychotic Quick Reference, updated October 2025 and revised April 2026, remains the most practical bedside table for dose conversions and missed-dose windows. The VA Atypical Antipsychotic LAI Drug Class Review is the cleanest single document for comparative effectiveness.
“The 90-day window is where LAIs are won or lost,” adds Lindsay Hill, DNP, PMHNP-BC. “A patient who gets one injection and one phone call is being set up to drop out. A patient who gets the injection plus three brief check-ins in the first month is the one who is still on the LAI a year later.”
The PMHNP decision algorithm
Three questions in order.
First, is the patient a candidate? Schizophrenia with any pattern of non-adherence, recent rehospitalization, first-episode psychosis, schizoaffective disorder, or bipolar I maintenance with a history of mixed features or rapid cycling — the answer is yes. The decision to offer the LAI happens before the decision of which molecule.
Second, which molecule? Aripiprazole if the patient tolerates aripiprazole and has metabolic risk that would worsen on a higher-affinity D2 blocker. Paliperidone if the patient tolerates risperidone or paliperidone and the prescriber wants the PP3M or PP6M off-ramp later. Risperidone (Uzedy) if the patient has bipolar I with a maintenance indication and prefers subcutaneous over intramuscular.
Third, which cadence? Start every patient on the shortest-interval formulation. Move them to the longer-interval formulation only after stability is documented for the labeled minimum period. Skipping straight to PP6M because “the patient prefers fewer shots” is how a stable patient becomes an inpatient.
The right framing for the patient conversation is simple: this is the format that gives you the lowest relapse rate. The data on first-episode psychosis is the data the patient should hear first — not a rehearsal of past non-adherence.
Frequently asked questions
Can a PMHNP prescribe long-acting injectable antipsychotics independently in every state?
Yes in the 28 full-practice-authority states. In reduced and restricted states, the answer is governed by the collaborative practice agreement — most CPAs do not specifically exclude LAIs, but the PMHNP should confirm before writing the first prescription. The injection itself may be administered by a trained RN under PMHNP order in most states; gluteal injection sites carry stricter rules in a small number of state nurse-practice acts.
Does Medicare Part B cover long-acting injectable antipsychotics?
Medicare Part B covers physician-administered injectable medications, including the antipsychotic LAIs, when the injection is given in the office. Buy-and-bill is the standard workflow. Part D covers the less common arrangement where the patient picks the drug up from a specialty pharmacy and brings it to the office. Most clinics route LAIs through Part B because the office handles drug acquisition, storage, and billing.
What is the actual cost of an LAI to a patient with commercial insurance?
Patient out-of-pocket varies widely. Every major LAI manufacturer offers a copay card that typically brings the patient cost to zero or near-zero for commercial plans. Medicaid patients pay the state’s nominal copay if any. The clinic should verify benefits and run the copay card before the patient leaves the office on injection day — a $1,800 sticker price the patient was not expecting is the fastest way to lose them from the protocol.
How long is the pharmacokinetic tail after the last LAI dose?
The tail runs weeks to months and varies by molecule. A patient who stops Invega Hafyera at month six has detectable paliperidone for up to a year. A patient who stops Abilify Asimtufii has detectable aripiprazole for three to six months. Risperidone LAIs (Consta, Uzedy) tail off over four to eight weeks. The PMHNP should not restart full-dose oral antipsychotic immediately after the last injection — the residual is still therapeutic for a meaningful window and stacking the oral can produce excessive plasma levels.
Does aripiprazole LAI need an oral overlap?
Yes. Both Abilify Maintena (monthly) and Abilify Asimtufii (every two months) require the patient to continue oral aripiprazole at the established dose for 14 days after the first injection, then taper. Skipping the 14-day overlap produces sub-therapeutic plasma levels in weeks two and three and is the leading reason a first LAI dose looks like it failed.
What is the Invega Sustenna loading regimen?
234 mg deltoid on day one, 156 mg deltoid on day eight (the eight-day window is fixed but tolerates plus or minus four days), then a monthly maintenance dose typically of 117 mg starting at week four to five. No oral overlap is required because the day-one and day-eight doses do the loading. The PMHNP should confirm the patient’s insurance approval window covers both loading doses before scheduling day one.
The bottom line. The LAI is not the same molecule as the oral medication. It is a different drug delivered through a different kinetic envelope, and every successful transition runs on a specific protocol that the PMHNP has to actually read.
The next concrete step: pull the package insert for the LAI the practice prescribes most often, read the “Initiation” and “Missed Doses” sections, and write the protocol on the wall above the injection-room sink.
Run the protocol. Every patient. Every time.
The Psych NP Fellowship is a 12-month clinical mentorship for new and early-career PMHNPs — case review, prescribing protocols, and the peer network that turns “I think I am doing this right” into “I know I am.”
This content is for educational purposes and does not replace individualized clinical judgment or supervision. Long-acting injectable antipsychotic prescribing is governed by the FDA-approved product labeling for each formulation, by state nurse-practice rules, and by the individual patient’s clinical picture. Consult the current package insert and your collaborating physician where applicable before initiating, transitioning, or discontinuing any LAI.
About the author. Lindsay Hill, DNP, PMHNP-BC is the founder of the Psych NP Fellowship, a 12-month clinical mentorship program for new and early-career psychiatric nurse practitioners. She is a published contributor to Psychiatric Times, past President of the Arizona APNA Chapter, and co-founder of the Psych NP Network.
